<DOC>
	<DOC>NCT02717091</DOC>
	<brief_summary>The aim of this study is to clarify the efficacy and safety of neoadjuvant FOLFIRINOX and nab-paclitaxel + gemcitabine for borderline resectable pancreatic cancer.</brief_summary>
	<brief_title>Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1. Borderline resectable pancreatic cancer (based on NCCN guideline version 2.2015) 2. first treatment for pancreatic cancer 3. performance status 0 or 1 4. adequate one marrow function 5. adequate renal function 6. obtained informed consent 1. other active concomitant malignancies 2. other severe medical conditions; contraindication of FOLFIRINOX, paclitaxel and gemcitabine 3. pregnant women 4. no informed consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>